Literature DB >> 30085081

Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Mathieu Iampietro1,2, Rodrigo I Santos1,2, Ndongala Michel Lubaki1,2, Alexander Bukreyev1,3,2.   

Abstract

A better understanding of the mechanisms used by Ebola virus to disable the host immune system and spread the infection are of great importance for development of new therapeutic strategies. We demonstrate that treatment of monocytic cells with Ebola virus shed glycoprotein (GP) promotes their differentiation resulting in increased infection and cell death. The effects were inhibited by blocking Toll-like receptor 4 pathway. In addition, high levels of shed GP were detected in supernatants of cells treated with Ebola vaccines. This study highlights the role of shed GP in Ebola pathogenesis and also in adverse effects associated with Ebola vaccines.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30085081      PMCID: PMC6249564          DOI: 10.1093/infdis/jiy406

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.

Authors:  Siddhartha Mahanty; Karen Hutchinson; Sudhanshu Agarwal; Michael McRae; Pierre E Rollin; Bali Pulendran
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

2.  Inflammatory responses in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; A J Georges; M-C Georges-Courbot; M Capron; I Bedjabaga; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

3.  Effect of culture conditions on the phenotype of THP-1 monocyte cell line.

Authors:  Paulomi B Aldo; Vinicius Craveiro; Seth Guller; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2013-04-29       Impact factor: 3.886

Review 4.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

5.  Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.

Authors:  Alexander Bukreyev; Andrea Marzi; Friederike Feldmann; Liqun Zhang; Lijuan Yang; Jerrold M Ward; David W Dorward; Raymond J Pickles; Brian R Murphy; Heinz Feldmann; Peter L Collins
Journal:  Virology       Date:  2008-11-17       Impact factor: 3.616

6.  Lipopolysaccharide-mediated cell activation without rapid mobilization of cytosolic free calcium.

Authors:  Herbert Bosshart; Michael Heinzelmann
Journal:  Mol Immunol       Date:  2004-08       Impact factor: 4.407

7.  Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression.

Authors:  Ang Yuan; Yi-Jing Hsiao; Hsuan-Yu Chen; Huei-Wen Chen; Chao-Chi Ho; Yu-Yun Chen; Yi-Chia Liu; Tsai-Hsia Hong; Sung-Liang Yu; Jeremy J W Chen; Pan-Chyr Yang
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

8.  Shed GP of Ebola virus triggers immune activation and increased vascular permeability.

Authors:  Beatriz Escudero-Pérez; Valentina A Volchkova; Olga Dolnik; Philip Lawrence; Viktor E Volchkov
Journal:  PLoS Pathog       Date:  2014-11-20       Impact factor: 6.823

9.  The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.

Authors:  Patrick Younan; Palaniappan Ramanathan; Jessica Graber; Fabian Gusovsky; Alexander Bukreyev
Journal:  MBio       Date:  2017-04-25       Impact factor: 7.867

10.  The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever.

Authors:  Kathleen H Rubins; Lisa E Hensley; Victoria Wahl-Jensen; Kathleen M Daddario DiCaprio; Howard A Young; Douglas S Reed; Peter B Jahrling; Patrick O Brown; David A Relman; Thomas W Geisbert
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  4 in total

Review 1.  Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.

Authors:  Amanda N Pinski; Ilhem Messaoudi
Journal:  Curr Opin Virol       Date:  2021-11-05       Impact factor: 7.090

2.  Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity.

Authors:  Satoko Yamaoka; Hideki Ebihara
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 3.  Activation of TLR4 by viral glycoproteins: A double-edged sword?

Authors:  Emily A Halajian; Emmanuelle V LeBlanc; Katrina Gee; Che C Colpitts
Journal:  Front Microbiol       Date:  2022-09-29       Impact factor: 6.064

Review 4.  Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion.

Authors:  Michelle L Pleet; Catherine DeMarino; Spencer W Stonier; John M Dye; Steven Jacobson; M Javad Aman; Fatah Kashanchi
Journal:  Viruses       Date:  2019-05-02       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.